Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation.
Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation.
复制标题
DOI：
10.2147/jbm.s93008
复制
发表时间：
2016
影响因子：
2
通讯作者：
Tanimoto M
中科院分区：
文献类型：
--
作者：
Nomura S;Maeda Y;Ishii K;Katayama Y;Yagi H;Fujishima N;Ota S;Moriyama M;Ikezoe T;Miyazaki Y;Hayashi K;Fujita S;Satake A;Ito T;Kyo T;Tanimoto M
包括全身照射(TBI)或环磷酰胺在内的预适应方案可以动员高迁移率族蛋白1(HMGB1)到外周血中。此外，纤溶酶原激活物抑制物(PAI)-1水平升高与异基因造血干细胞移植(AHSCT)有关。然而，造血干细胞移植后循环中HMGB1水平的变化却知之甚少。研究队列包括289名在日本25家机构中的一家接受AHSCT的患者。我们研究了HMGB1与PAI-1在急性HSCT后的关系。HMGB1水平在条件化治疗后显著增加。此外，在TBI+患者和环磷酰胺/TBI患者中，0天时HMGB1水平显著升高。我们的数据显示，移植后第0天HMGB1水平的升高与移植后PAI-1的升高相关，这与以前的报道一致。因为PAI-1可以促进促凝血活性，所以在预适应方案后第0天升高的HMGB1可能在移植后的移植相关凝血障碍中起作用。
Conditioning regimens including total body irradiation (TBI) or cyclophosphamide can mobilize high-mobility group box 1 (HMGB1) to peripheral blood. Additionally, increased plasminogen activator inhibitor (PAI)-1 levels are associated with post-allogeneic hematopoietic stem cell transplantation (aHSCT). However, changes to circulating levels of HMGB1 after aHSCT are poorly understood. The study cohort included 289 patients who underwent aHSCT at one of 25 institutions in Japan. We have investigated the relationship between HMGB1 and PAI-1 following aHSCT. A significant increase in HMGB1 levels occurred after conditioning treatment. Additionally, levels of HMGB1 at day 0 were significantly increased in TBI+ patients and cyclophosphamide/TBI patients. Our data revealed that an increased level of HMGB1 at day 0 following aHSCT correlates with increased PAI-1 after aHSCT, which is consistent with previous reports. Increased HMGB1 at day 0 after a conditioning regimen may play a role in transplantation-associated coagulopathy following aHSCT, because PAI-1 can accelerate procoagulant activity.